Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 783-790

  Schubert, Antje ^a   Hawighorst, Thomas ^a   Emons, Günter ^a   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Breast cancer; GnRH analogs; Metastasis

Indexed keywords

CETRORELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; TRIPTORELIN;

ALU SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME;

ALU ELEMENTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, LHRH; RECEPTORS, PROGESTERONE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82255169351     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1358-9     Document Type: Article

References (36)

1. Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. IARC Press, Lyon
2. SJ Dawson E Provenzano C Caldas 2009 Triple negative breast cancers: clinical and prognostic implications Eur J Cancer 45 1 27 40 19775602 10.1016/S0959-8049(09)70013-9
3. G Konecny G Pauletti M Pegram M Untch S Dandekar Z Aguilar C Wilson HM Rong I Bauerfeind M Felber HJ Wang M Beryt R Seshadri H Hepp DJ Slamon 2003 Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 2 142 153 12529347 10.1093/jnci/95.2.142 1:CAS:528:DC%2BD3sXovFelug%3D%3D (Pubitemid 36193263)
4. MJ Kim JY Ro SH Ahn HH Kim SB Kim G Gong 2006 Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes Hum Pathol 37 9 1217 1226 16938528 10.1016/j.humpath.2006.04.015 1:CAS:528:DC%2BD28XovVWrt7k%3D (Pubitemid 44286991)
5. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks M van de Rijn CM Perou 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 16 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
6. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 9 1721 1728 17387718 10.1002/cncr.22618 (Pubitemid 46668532)
7. M Lacroix 2006 Significance, detection and markers of disseminated breast cancer cells Endocr Relat Cancer 13 4 1033 1067 17158753 10.1677/ERC-06-0001 1:CAS:528:DC%2BD2sXisFaktrY%3D (Pubitemid 46212562)
8. TA Guise WM Kozlow A Heras-Herzig SS Padalecki JJ Yin JM Chirgwin 2005 Molecular mechanisms of breast cancer metastases to bone Clin Breast Cancer 5 Suppl 2 S46 S53 15807924 10.3816/CBC.2005.s.004 1:CAS:528:DC%2BD2MXktFyhsrw%3D
9. R Tomin WL Donegan 1987 Screening for recurrent breast cancer-its effectiveness and prognostic value J Clin Oncol 5 1 62 67 3806160 1:STN:280:DyaL2s7htFKrtQ%3D%3D (Pubitemid 17007857)
10. OK Schlappack M Baur G Steger C Dittrich K Moser 1988 The clinical course of lung metastases from breast cancer Klin Wochenschr 66 17 790 795 3184763 10.1007/BF01726581 1:STN:280:DyaL1M%2FjvVWlsQ%3D%3D
11. M Selzner MA Morse JJ Vredenburgh WC Meyers PA Clavien 2000 Liver metastases from breast cancer: long-term survival after curative resection Surgery 127 4 383 389 10776428 10.1067/msy.2000.103883 1:STN:280: DC%2BD3c3jvVOhug%3D%3D (Pubitemid 30225989)
12. M Fekete JL Wittliff AV Schally 1989 Characteristics and distribution of receptors for [d-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer J Clin Lab Anal 3 3 137 147 2569034 10.1002/jcla.1860030302 1:CAS:528:DyaL1MXktFygsr0%3D (Pubitemid 20199263)
13. KH Baumann L Kiesel M Kaufmann G Bastert B Runnebaum 1993 Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters Breast Cancer Res Treat 25 1 37 46 8390871 10.1007/BF00662399 1:STN:280: DyaK3s3pvV2gtw%3D%3D (Pubitemid 23107734)
14. T Moriya T Suzuki M Pilichowska N Ariga N Kimura N Ouchi H Nagura H Sasano 2001 Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma Pathol Int 51 5 333 337 11422790 10.1046/j.1440-1827.2001.01210.x 1:STN:280:DC%2BD3Mzmt12ntw%3D%3D (Pubitemid 32589020)
15. A Mangia S Tommasi SJ Reshkin G Simone B Stea F Schittulli A Paradiso 2002 Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and Western blot analyses Oncol Rep 9 5 1127 1132 12168084 1:CAS:528:DC%2BD38XmvVensr8%3D
16. S Fister AR Günthert G Emons C Gründker 2007 Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo Cancer Res 67 4 1750 1756 17308117 10.1158/0008-5472.CAN-06-3222 1:CAS:528: DC%2BD2sXhvVWqur8%3D (Pubitemid 46383402)
17. S Fister AR Günthert B Aicher KW Paulini G Emons C Gründker 2009 GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax Cancer Res 69 16 6473 6481 19638591 10.1158/0008-5472.CAN-08-4657 1:CAS:528:DC%2BD1MXpvFejsLw%3D
18. C Gründker C Föst S Fister N Nolte AR Günthert G Emons 2010 Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo Breast Cancer Res 12 4 R49 20630060 10.1186/bcr2606
19. J von Alten S Fister H Schulz V Viereck KH Frosch G Emons C Gründker 2006 GnRH analogs reduce invasiveness of human breast cancer cells Breast Cancer Res Treat 100 13 21 10.1007/s10549-006-9222-z
20. G Emons O Ortmann M Becker G Irmer B Springer R Laun F Hölzel KD Schulz AV Schally 1993 High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines Cancer Res 53 22 5439 5446 8221683 1:CAS:528:DyaK2cXks1antA%3D%3D (Pubitemid 23342164)
21. G Emons B Schröder O Ortmann S Westphalen KD Schulz AV Schally 1993 High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines J Clin Endocrinol Metab 77 6 1458 1464 8263128 10.1210/jc.77.6.1458 1:CAS:528:DyaK2cXitl2nuw%3D%3D (Pubitemid 24000896)
22. G Irmer C Bürger R Müller O Ortmann U Peter SS Kakar JD Neill KD Schulz G Emons 1995 Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma Cancer Res 55 4 817 822 7850795 1:CAS:528:DyaK2MXjsleltrc%3D
23. A Sasaki BF Boyce B Story KR Wright M Chapman R Boyce GR Mundy T Yoneda 1995 Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice Cancer Res 55 16 3551 3557 7627963 1:CAS:528: DyaK2MXnsFGhsrw%3D
24. Koch M, Hussein F, Woeste A, Gründker C, Frontzek K, Emons G, Hawighorst T (2010) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat. doi: 10.1007/s10549-010-1085-7
25. T Olbrich E Ziegler G Türk A Schubert G Emons C Gründker 2010 Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: evidence for a dose-window effect Gynecol Oncol 119 3 571 578 20832102 10.1016/j.ygyno.2010.08.018 1:CAS:528:DC%2BC3cXhtlyrtbrE
26. L Castillo-Pichardo MM Martinez-Montemayor JE Martinez KM Wall LA Cubano S Dharmawardhane 2009 Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols Clin Exp Metastasis 26 6 505 516 19294520 10.1007/s10585-009-9250-2 1:CAS:528:DC%2BD1MXptFClsLk%3D
27. JE Price A Polyzos RD Zhang LM Daniels 1990 Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice Cancer Res 50 3 717 721 2297709 1:STN:280:DyaK3c7isVansA%3D%3D (Pubitemid 20054204)
28. DR Welch 1997 Technical considerations for studying cancer metastasis in vivo Clin Exp Metastasis 15 3 272 306 9174129 10.1023/A:1018477516367 1:STN:280:DyaK2szhs1ymtw%3D%3D (Pubitemid 27240358)
29. M Skobe T Hawighorst DG Jackson R Prevo L Janes P Velasco L Riccardi K Alitalo K Claffey M Detmar 2001 Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis Nat Med 7 2 192 198 11175850 10.1038/84643 1:CAS:528:DC%2BD3MXhtVylu7s%3D (Pubitemid 32148486)
30. DT Ross U Scherf MB Eisen CM Perou C Rees P Spellman V Iyer SS Jeffrey M Van de Rijn M Waltham A Pergamenschikov JC Lee D Lashkari D Shalon TG Myers JN Weinstein D Botstein PO Brown 2000 Systematic variation in gene expression patterns in human cancer cell lines Nat Genet 24 3 227 235 10700174 10.1038/73432 1:CAS:528:DC%2BD3cXhvFaqtrg%3D (Pubitemid 30132189)
31. G Ellison T Klinowska RF Westwood E Docter T French JC Fox 2002 Further evidence to support the melanocytic origin of MDA-MB-435 Mol Pathol 55 5 294 299 12354931 10.1136/mp.55.5.294 1:CAS:528:DC%2BD38XovFKhu74%3D (Pubitemid 35193254)
32. S Sellappan R Grijalva X Zhou W Yang MB Eli GB Mills D Yu 2004 Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line Cancer Res 64 10 3479 3485 15150101 10.1158/0008-5472.CAN-3299- 2 1:CAS:528:DC%2BD2cXktVWhsLs%3D (Pubitemid 38657921)
33. S Buchholz S Seitz AV Schally JB Engel FG Rick L Szalontay F Hohla A Krishan A Papadia T Gaiser G Brockhoff O Ortmann K Diedrich F Koster 2009 Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition Int J Oncol 35 4 789 796 19724914 1:CAS:528:DC%2BD1MXht1Wju7nE
34. RM Moretti M Montagnani Marelli JC Van Groeninghen P Limonta 2002 Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells J Clin Endocrinol Metab 87 8 3791 3797 12161512 10.1210/jc.87.8.3791 1:CAS:528:DC%2BD38XmtF2gt7o%3D (Pubitemid 34879529)
35. VJ Gnanapragasam S Darby MM Khan WG Lock CN Robson HY Leung 2005 Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer J Pathol 206 2 205 213 15818594 10.1002/path.1767 1:CAS:528: DC%2BD2MXlsFejur8%3D (Pubitemid 40754024)
36. C Yates A Wells T Turner 2005 Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline Br J Cancer 92 2 366 375 15655536 1:CAS:528:DC%2BD2MXhtFWgsbo%3D (Pubitemid 40343154)